Clinical efficacy analysis of amiodarone in the treatment of emergency coronary heart disease patients with concomitant tachyarrhythmia
胺碘酮治疗急诊冠心病合并快速性心律失常患者的临床疗效分析

摘要

目的 深入且细致地分析和探讨胺碘酮在治疗急诊冠心病合并快速性心律失常患者中的临床疗效，期望将所有研究成果有效应用于临床实践，从而推动该领域的发展进程，更好地保障患者生命健康。方法 设立2023年9月至2024年9月为研究期限，纳入90例急诊收治的冠心病合并快速性心律失常患者为研究对象，遵循“平行序贯”分组原则，利用数字表划分法实施小组划分，每组分配（n=45），分别命名为参照组与研究组。前者采取静脉注射利多卡因负荷量+维持量治疗。后者采取静脉注射安碘酮负荷量+维持量治疗，最终收集整理相关数据，统计归纳临床资料，评价比对治疗效果。比对数据包含：心律失常转复率、转复时间、心功能改善情况、不良反应发生率。结果 试验毕，统计学分析后发现，研究组患者在左室射血分数（LVEF）提升幅度、心功能NYHA分级改善程度、不良反应发生率方面体现，均显优参照组，P值＜0.05，值得探讨。结论 对于冠心病合并快速心律失常的患者来说，在其临床治疗方案的横向选择中，建议优先考虑并采用研究组所提出的实施方案。该方案不仅能迅速且有效地恢复患者的心律，显著提升其心功能状况，而且在安全性方面亦展现出极高的保障水平。总体而言，此治疗方案具备显著优势，值得在急诊临床实践中广泛推广与应用，以期惠及更多患者，带来积极的治疗成效。

Abstract

Objective To analyze and explore in depth the clinical efficacy of amiodarone in the treatment of emergency coronary heart disease patients with concomitant tachyarrhythmia, with the hope of effectively applying all research results to clinical practice, thereby promoting the development process of this field and better safeguarding the life and health of patients.
Methods The study period was set from September 2023 to September 2024, and 90 patients with coronary heart disease and rapid arrhythmia admitted to the emergency department were included as the research subjects. Following the principle of "parallel sequential" grouping, the numerical table division method was used to implement group division, and each group was assigned (n=45), named as the reference group and the study group, respectively. The former adopts intravenous injection of lidocaine loading dose+maintenance dose treatment. The latter adopts intravenous injection of amiodarone loading dose+maintenance dose treatment, and finally collects and organizes relevant data, summarizes clinical data, evaluates and compares treatment effects. The comparison data includes: arrhythmia conversion rate, conversion time, improvement of cardiac function, and incidence of adverse reactions.
Results After the completion of the experiment and statistical analysis, it was found that the study group showed significant improvement in left ventricular ejection fraction (LVEF), NYHA grading of cardiac function, and incidence of adverse reactions compared to the reference group, with a P value of<0.05, which is worth exploring.
Conclusion   For patients with coronary heart disease complicated by rapid arrhythmia, it is recommended to prioritize and adopt the implementation plan proposed by the research group in the horizontal selection of clinical treatment plans. This plan not only quickly and effectively restores the patient's heart rhythm and significantly improves their cardiac function, but also demonstrates a high level of safety assurance. Overall, this treatment plan has significant advantages and is worthy of widespread promotion and application in emergency clinical practice, in order to benefit more patients and bring positive treatment outcomes.